Science

Jan 20, 2025, 13:55

Emre Yekedüz: New findings in high-risk NMIBC after BCG failure

Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University, posted on X about recent paper by Charalampos Fragkoulis et al., titled “Intravesical Administration of Durvalumab for High-risk Non–muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group” published on Science Direct.

Authors: Charalampos Fragkoulis, Aristotelis Bamias, Nikos Gavalas, Kimon Tzannis, Evangelos Fragiadis, Alexandros Pinitas, Panayiotis V. Stamatakos, George Papadopoulos, George Stathouros, Xanthippi Grammatoglou, Penelope Korkolopoulou, Christina Zoubouli, Konstantinos Stravodimos, Konstantinos Ntoumas, Dionysios Mitropoulos, Andreas Skolarikos, Athanasios Papatsoris

“New findings in high-risk NMIBC after BCG failure.

Single-arm phase 2 trial tested intravesical durvalumab (1000 mg every 6 weeks) in 30 patients.

1-yr high-grade relapse-free rate: 39%
Bladder-intact survival at 1 yr: 78%
Minimal toxicity: Grade 1 haematuria in 17% of patients.”

Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington, retweeted Emre Yekedüz’s post, adding the following:

“Proud of my Greek colleagues: Hellenic GU cancer group: trial with intravesical durvalumab!”

Alexandros Pinitas Andreas Skolarikos Aristotelis Bamias Athanasios Papatsoris cancer Charalampos Fragkoulis Christina Zoubouli Dionysios Mitropoulos Emre Yekedüz Evangelos Fragiadis George Papadopoulos George Stathouros Kimon Tzannis Konstantinos Ntoumas Konstantinos Stravodimos Nikos Gavalas NMIBC OncoDaily Oncology Panayiotis V. Stamatakos Penelope Korkolopoulou Science Direct Xanthippi Grammatoglou

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer